NRx Pharmaceuticals
1,510 posts
NRx Pharmaceuticals
@NRxPharma
We draw upon decades of collective, scientific, & drug-development experience to address very high unmet needs of patients and bring improved health to patients
- Today we announced promising data from a cohort of patients with Critical #COVID19 who received our investigational drug aviptadil (#RLF100) under the U.S. FDA Expanded Access Protocol. Learn more: prn.to/34Ny360
- Today we announced initial results of 72% survival in our ongoing open label Expanded Access Program for patients with Critical #COVID19 receiving SOC and treated with our investigational drug aviptadil (#RLF100). Read the press release: prn.to/3fC5mhl
GIF - Today we announced having met the target enrollment of 165 patients in our Phase 2b/3 #clinicaltrial of aviptadil (#RLF100) for Critical #COVID19. Read the press release: prn.to/39NMgUu
- NRx has validated the first commercial formulation of its medicine for Critical #COVID-19, allowing for high volume manufacture, as potential regulatory approvals are obtained. Read more in the press release here: bit.ly/3BtUD39
- Today we shared additional data on ZYESAMI™ (aviptadil) showing a 10 day accelerated recovery from respiratory failure among patients with Critical #COVID19 treated with high flow nasal oxygen. Learn more: prn.to/37GASrG
GIF - .@CDCgov has reported over 300,000 new #COVID19 cases in the last 7 days. With cases on the rise, the need for effective treatments is greatly emphasized. Follow our journey at neurorxpharma.com More COVID-19 stats from the CDC: cdc.gov/coronavirus/20… #aviptadil
- Aviptadil (#RLF100) is thought to protect against Critical #COVID19 by binding to the Alveolar Type II lung cells that are targeted by #SARSCoV2. Learn more about the MOA and follow our journey at bit.ly/31uSgws #aviptadil
00:00 - Yesterday, the Data Monitoring Committee (DMC) voted unanimously that our study of #aviptadil (RLF-100™) in Critical #COVID-19 patients should continue as planned. Follow our journey at NeuroRxpharma.com Read more: prnewswire.com/news-releases/…
00:00 - Today we announced the submission of our request for Emergency Use Authorization for aviptadil (#RLF100) in patients with Critical COVID-19 who who have exhausted all approved treatments: prn.to/3kK6Jfs Follow our journey: neurorxpharma.com
- NRx completed phase 2b/3 data analysis of ZYESAMI™ for #COVID19 respiratory failure treatment. Investor call on 3/29 @ 8:30am EDT. Dial 866-373-3402 or webcast @ bit.ly/3sqPyDS prn.to/3flNc5k #aviptadil #ZYESAMI #pandemic #SARSCoV2 #coronavirus #biotech
- NeuroRx is one of only four companies to receive Fast Track Designation from the FDA for an investigational drug to treat Critical #COVID19. Follow our NeuroRx journey to develop aviptadil (#RLF100): neurorxpharma.com Learn more about Fast Track: fda.gov/patients/fast-…
- Today we announced that we have enrolled 150 patients (out of a targeted enrollment of 165) in our ongoing Phase 2b/3 trial of #RLF100 in Critical #COVID19. Read the press release: prn.to/2ICD21L
